stockrowLatest quarter
Tempus AI reported Q2 FY2026 revenue of $382.5 million, above the $381.0 million consensus and up from $314.6 million a year earlier. Its adjusted EPS was −$0.04, above the consensus estimate.
The company’s filing attributed revenue growth to increased clinical oncology and hereditary testing volumes and more data deliveries. Tempus reported Diagnostics revenue growth of 20.0% and Insights revenue growth of 36.0%.
Gross margin rose to 64.4% from 62.0%, while operating margin was −19.8%, compared with −19.6% a year earlier. Tempus reported diluted EPS of $0.03, compared with −$0.25 in the prior-year quarter. Its filing attributed a rise in other income primarily to unrealized gains on marketable equity securities.
Free cash flow was −$18.6 million, compared with $34.7 million a year earlier.
| Q2 FY2026 | Q2 FY2025 | Change | |
|---|---|---|---|
| Revenue | $382.5 million | $314.6 million | 21.6% |
| Diluted EPS | $0.03 | −$0.25 | — |
| Gross margin | 64.4% | 62.0% | 2.5 percentage points |
| Operating margin | −19.8% | −19.6% | −0.2 percentage points |
| Free cash flow | −$18.6 million | $34.7 million | −153.7% |
| Against the consensus | Reported | Consensus | Result |
|---|---|---|---|
| Revenue | $382.5 million | $381.0 million | In line |
Adjusted EPS is the figure the consensus estimates, not the GAAP EPS above.
What management said on the call
In its quarterly filing, Tempus said it plans to invest in new assays and expand into new disease areas. The company also expects operating expenses to rise as it develops new offerings, expands its sales organization and increases marketing.
Guidance
Tempus raised its full-year revenue guidance for FY2026 to approximately $1.6 billion in its results release, revising the outlook it had previously provided for the year.
| Metric | For | Guide | Previous guide | Change |
|---|---|---|---|---|
| EBITDA, non-GAAP | FY2026 | $65.0 million | — | New |
| Revenue | FY2026 | $1.6 billion–$1.6 billion | — | New |